FATE earnings analysis
What we found in FATE's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Fate Therapeutics reported Q2 2026 revenue of $2.082 million, up approximately 9.2% year over year, while diluted EPS improved to $(0.25) from $(0.29) in Q2 2025. The company had $153.8 million of cash, cash equivalents and investments as of June 30, 2026, supporting management’s stated operating runway into 2028. Clinical progress—including FDA clearance for FT839 in July 2026 and FT819’s May 2026 CDRP selection—is balanced by continued losses, substantial funding requirements and regulatory, manufacturing and clinical-execution risks.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue increased 9.2% year over year
- Q2 2026 revenue was $2.082 million, up from $1.907 million in the prior-year quarter, an increase of $0.175 million, or approximately 9.2%.
- EPS loss narrowed year over year
- Diluted EPS was $(0.25), improving from $(0.29) in Q2 2025 by $0.04 per share and from $(0.26) in Q1 2026 by $0.01 per share.
- Cash runway extends into 2028
- Cash, cash equivalents and investments totaled $153.8 million as of June 30, 2026, and management expects this balance to support an operating runway into 2028.
- FT839 received FDA clinical clearance
- The FDA cleared FT839 for clinical research in July 2026. FT839 is described as an off-the-shelf CAR T-cell candidate engineered to co-target CD19 and CD38.
- FT819 entered FDA CMC pilot
- FT819 was selected for the FDA’s CMC Development and Readiness Pilot Program in May 2026, providing additional CMC-focused interaction with the FDA, although the filing cautions that participation may not accelerate development or manufacturing readiness.
- No material control changes reported
- Management reported effective disclosure controls as of June 30, 2026, with no changes in internal control over financial reporting that materially affected, or were reasonably likely to materially affect, controls during the quarter.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Continued funding need and accumulated losses
- The company has not obtained regulatory approval for any product candidate and has not generated revenue from therapeutic product sales. As of June 30, 2026, accumulated deficit was $1.6 billion, while current operations continue to require substantial additional funding.
- FDA pilot participation may not accelerate approval
- FT819’s participation in the FDA CDRP Program does not assure faster development, review or approval. The company was accepted into the program in May 2026, but the filing states that FDA may remove a product candidate from the program if continued support is not justified by clinical-development data.
- China vendor restrictions may delay trials
- The company faces increased geopolitical and supply-chain risk from vendors in China or affiliated with Chinese companies. The BIOSECURE Act was enacted on December 18, 2025, and replacement vendors could be more expensive, have longer lead times or lack comparable technical capabilities.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.25
What they said about what is next.
No numeric revenue or EPS guidance was provided. Management maintained an expectation for an operating runway into 2028, supported by $153.8 million of cash, cash equivalents and investments.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 13, 2026
- Fate Therapeutics reported a disappointing Q1 for 2026, with revenues of $1.3 million, falling short of expectations, while EPS loss of $0.26 was better than the anticipated loss of $0.32. Management indicated a…
- 10-K · February 26, 2026
- Fate Therapeutics, Inc. reported a total revenue of $1 million for Q4 2025, a decrease from $2 million in the prior quarter, with corresponding operating losses and net losses increasing sharply, driven by significant…
- 10-Q · November 13, 2025
- Fate Therapeutics, Inc. reported strong Q3 results with actual revenues of $1.74 million, exceeding expectations and significantly higher than the previous year's $3.07 million. While still operating at a loss, they…
- 10-Q · August 12, 2025
- Fate Therapeutics reported significant revenue growth in Q2 2025 with actual revenue reaching $1.9 million, a 38% decrease from $6.8 million the previous year but a remarkable surprise against the expected $947,940,…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing FATE makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever